Kornimate/medical-research-clean huggingface dataset:
prospective evaluation of jugular vein thrombi after cpb cervical cannulation

Conditions: Post-interventional VJI Thrombi After CPB

Summary: the primary objective of the study is to prospectively analyse the occurrence of post-interventional internal vena jugularis (vji) thrombi after minimally invasive cardiac surgery using a vji cannula to perform cardiopulmonary bypass (cpb). the study follows the question whether the performance of a jugular cannulation for the operation under cpb regularly causes wall thromboses despite continuous anticoagulation and a short length of stay of a few hours. the thromboses to be assessed for the study will be obtained by bedside (doppler) sonography by experienced intensive care physicians in the cardiac surgery intensive care unit. a prospective analysis of all minimal invasive procedures performed with regard to thrombi in the vji.


Eligibility criteria:
inclusion criteria: - minimally invasive cardiac surgery carried out using complete cardiopulmonary bypass. exclusion criteria: * postoperative support by veno-venous or veno-arterial extracorporeal membrane oxygenation. * complications of neck cannula placement or removal. * pre-existing occlusion of the vena jugularis interna * pre-existing thrombosis of the vena jugularis interna * pre-existing prothrombotic coagulation disorder * existing catheterisation of the vena jugularis interna within 14 days * pre-existing anatomical anomaly of the vena jugularis interna
bowen and graston technique in patients of tension neck syndrome

Conditions: Neck Syndrome

Summary: to compare the effects of bowen and graston technique in tension neck syndrome for neck pain , rom and disability in patients with tension neck syndrome .

tension neck syndrome (tns) is defined as a myofascial pain localized in the neck and shoulder regions. the symptoms include; pain, tenderness, fatigue and stiffness in the neck and shoulder musculature, headaches radiating from the neck, without a history of injury herniated cervical disk, or degenerative processes. it is characterized pain over the neck region and muscle tenderness elicited on palpation and or neck movement. tns patients with pain have the reduced sensitivity of the neck proprioception. tn may be work- and individual-related and sociopsychological factors may have effect. bowen therapy, is a dynamic fascial and muscle release approach, consisting of gentle cross-fiber movements applied to the fascia, muscles, tendons, muscle insertions, muscle septa, ligaments and viscera. grastοn technique is an instrument assisted soft tissue treatment method (іastm) derived from the cyriax1 cross-friction massage. physіοtherapist strikes stainless steel instrument in a longitudinal dіrectіοn and in circular patterns at the treatment site

Eligibility criteria:
inclusion criteria: 1. age group 20-45 2. both males and females 3. patients diagnosed with vdts induced tension neck syndrome in upper trapezius, scm \& levator scapulae muscles. 4. specific criteria will be applied to make diagnosis of visual display terminal syndrome: syndrome, requiring 3 or more symptoms from the following: patients from tension neck syndrome such as neck pain, stiffness \& tenderness, fatigue or feeling of tiredness, possible headache, pain during movement etc. within past 7 days musculoskeletal discomfort (pain, tenderness \& stiffness)in shoulder, elbow, lower back \& wrist/hand regions ocular symptoms i.e. eye strain or eye dryness from past 7 days 5. desktop, laptop and excessive smartphone users for more than 2 hours per day at eye level with extreme neck position and static work posture for at least 5 days per week exclusion criteria: 1. cervical radiculopathy 2. uncontrolled systemic disease 3. neck pain due to diabetes, trauma, fracture, infectious or inflammatory process 4. previous neck or shoulder surgery 5. patients who are using any medication to reduce the neck pain \& discomfort 6. malignancy

Keywords: neck pain neck disability instrument assisted soft tissue treatment method
the molecular epidemiology of epidermal growth factor receptor (egfr) mutations in patients with advanced egfr mutation-positive non-small cell lung cancer treated with afatinib

Conditions: Non Small Cell Lung Cancer; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Gene Mutation

Summary: this is an observational, non-interventional, single-country, multi center, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc) who had been treated with afatinib at any line.

this is an observational, non-interventional, single-country, multicenter, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic egfr mutation-positive nsclc who had been treated with afatinib s at any line. the study is carried out by hospital-based oncologists/pneumonologists specializing in lung cancer under real-world conditions of daily clinical practice. investigators were selected through a documented and structured feasibility process which accounted for physicians' qualifications, previous participation and experience in similar clinical studies, recruitment potential, and retention capability. in addition, in order to represent variations in current real-world patterns of care, research sites were recruited from various geographic regions in greece, also taking into consideration the regional setting and type of healthcare site/institution (publicly/privately owned, specialized oncology/pulmonology clinic, university clinic).

Eligibility criteria:
inclusion criteria: * \>18 years old * patients diagnosed with non-small cell lung cancer * metastatic disease * afatinib treated in any line * egfr mutated exclusion criteria: -
abdominal free air after surgery

Conditions: Prediction of Gastrointestinal Perforation

Summary: the aim of this study is to evaluate if the presence of abdominal free air on a plain chest radiograph predicts gastrointestinal perforation. we aimed to enroll all patients undergoing abdominal surgery reporting major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.


Eligibility criteria:
inclusion criteria: * abdominal surgery and major symptoms and signs suggestive of gastrointestinal perforation within the third postoperative day. exclusion criteria: * inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes.

Keywords: pneumoperitoneum free air surgery perforation radiograph
exploratory study to investigate the reparative and regenerative potential of alemtuzumab in relapsing-remitting multiple sclerosis patients participating in the care ms i and ms ii studies

Conditions: Multiple Sclerosis

Summary: the primary goal of this study will be to explore the reparative and regenerative potential of alemtuzumab in rrms patients who are participating in the care ms i and care ms ii studies using conventional and non-conventional mri sequences.


Eligibility criteria:
inclusion criteria: * participating in either the care ms i or care ms ii studies exclusion criteria: * not a participant in the care ms i or care ms ii studies

Keywords: patients with rrms who are participating in the care ms i and care ms ii
neonatal hypoxic ischemic encephalopathy : safety and feasibility study of a curative treatment with autologous cord blood stem cells

Conditions: Neonatal Hypoxic-ischaemic Encephalopathy

Summary: neonatal hypoxic-ischaemic encephalopathy is a dramatic perinatal complication due to brain asphyxia. neurological and neurosensory sequelae are frequent in survivors, due to neuronal damage and loss. currently, only total or partial body hypothermia can partially prevent cell loss. however, no treatment exists to restore neuronal functions. cord blood stem cells are a promising treatment for the near future. the primary objective of this study is to test the safety and feasibility of a curative treatment with autologous cord blood stem cell in neonatal hypoxic-ischaemic encephalopathy. the secondary objectives are to test the efficacy of this curative treatment with cell with neurogenic potential on the prevention of neurologic sequelae, as well as to test the optimum timing of cell preparation administration


Eligibility criteria:
inclusion criteria: term ≥ 36 weeks of gestation * and (2) : * a blood ph \ 12 mmol/l (at birth or within 60 minutes of age) * or a blood ph between 7,01 and 7,15, with additionnal criteria: * a history of acute perinatal event (e.g : abnormal fetal cardiac rate, cord prolapse, uterine rupture, maternal hemorrhage) * and a 5 minutes apgar score ≤ 5, or a continued need for resuscitation, including endotracheal or mask ventilation at 5 min after birth. * signs of encephalopathy within 12 hours of age (sarnat and sarnat classification, score ≥ 2) * ± abnormal electroencephalogram or aeeg within 12 hours of age * therapeutic hypothermia. * no maternal infection with vih, htlv 1 or 2, hepatitis b or c virus. * maternal negative serology for syphilis * written parental consent exclusion criteria: * presence of known chromosomal anomaly. * presence of major congenital anomalies. severe intrauterine growth restriction (weight \<1800g) * infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist.
application of lung near-infrared spectroscopy (nirs) in preterm infants

Conditions: Respiratory Distress Syndrome, Newborn

Summary: premature infants are more likely to develop hypoxemia after birth often requiring invasive and non-invasive mechanical ventilation and surfactant therapy to improve alveolar gas exchange and oxygen transport. near-infrared spectroscopy (nirs) has been used to detect pulmonary regional oxygen saturation (rpso 2 ) as well as cerebral regional oxygen saturation (rcso2 ) and evaluate the oxygenation state of the lung and brain. this is a prospective observational study to evaluate utility of rpso2 and compare it with rcso2 in preterm infants born between 23-32 weeks of gestation receiving noninvasive ventilation and surfactant treatment. enrolled patients will be continuously studied with placement of nirs monitor using cerebral sensor (invos™) for 6 hrs and 15 min before and after surfactant administration. pulmonary regional oxygen saturation (rpso2) with a sampling interval of 6 s will be followed for 6hrs.


Eligibility criteria:
inclusion criteria: infants born between 23-32 weeks of gestation admitted to the neonatal intensive care unit with respiratory distress receiving non-invasive ventilation and requiring surfactant replacement therapy. exclusion criteria: neonates with no need for respiratory support/surfactant. neonates with congenital malformations.
pea protein and postprandial response (pea)

Conditions: Metabolic Syndrome

Summary: the main objective is to investigate the postprandial effect of arginine-rich protein (i.e. pea-protein) on metabolic control, inflammation and endothelial function after a high-fat meal in subjects with characteristics of the metabolic syndrome.

arginine is potential interesting considering the metabolic syndrome. studies so far indicated both long-term effects, as well as acute - postprandial - actions; especially when metabolism is already challenged, e.g. in diabetic patients or after a high-fat meal. if arginine-rich proteins are equally effective is not known. therefore we are interested in the effect of (arginine rich) protein on postprandial (dys)metabolism, inflammation and endothelial function, within 6 hours after a meal.

Eligibility criteria:
inclusion criteria: * male gender * central obesity: waist circumference ≥94 cm plus any one of the following four factors: * raised triglyceride level: ≥1.7 mmol/l; * reduced high-density lipoprotein (hdl) cholesterol: \<1.03 mmol/l * raised blood pressure: systolic blood pressure ≥130 mmhg or diastolic bp ≥85 mmhg or use of blood pressure lowering medication * raised fasting plasma glucose ≥ 5.6 mmol/l additional inclusion criteria: * age 45-70 years * body weight should be stable for 3 months * stable exercise habits during the last 6 months, and not participating in any vigorous exercise program exclusion criteria: * tobacco smoking * (undiagnosed) diabetes - but not impaired fasting glucose (ifg) and/or impaired glucose tolerance (igt) as evaluated by an oral glucose tolerance test at screening * active hearth disease, i.e. history of myocardial infarction or angina pectoris * following, or have recently followed a (weight-loss) diet * drug uses knowing to interfere with the objectives of the study * oral corticosteroids, lipid-lowering drugs (statins) * allergic to cow milk / dairy products or gluten * vegetarians * received inoculations within 2 months of starting or planned to during the study * donated or intended to donate blood 2 months before till two months after the study * abuse of drugs and/or alcohol * participation in another biomedical study within 1 month before the first screening visit * not agreeable to be informed about possible distorted blood values which could be found by screening
a randomized controlled trial on malaria primaquine treatment in timika, indonesia (tripi)

Conditions: Uncomplicated Malaria

Summary: plasmodium vivax can form dormant liver stages that reactivate weeks or months following an acute infection. recurrent infections can be associated with a febrile illness, a cumulative risk of severe anaemia, and even mortality. in co-endemic areas the risk of recurrence after both p. vivax and p. falciparum infections can be over 50% within 3 months. the only drug we have to kill p. vivax hypnozoites is primaquine which is currently given as a 14 day regimen. in papua a retrospective study found very low effectiveness for unsupervised treatment. if true this has profound effects on treatment policy, suggesting that greater efforts are needed to encourage adherence to treatment. we propose a cluster randomized, controlled, open label trial to assess the effectiveness of unsupervised versus supervised primaquine treatment in patients with uncomplicated malaria. since the risk of recurrent p. vivax is high in patients with either p. vivax or p. falciparum, both infections will be included in the study. the study will be conducted in mimika, in the southern part of papua province, indonesia. participants will be enrolled at village health posts and provided with schizontocidal treatment plus primaquine radical cure which will be either supervised or unsupervised depending on which cluster the clinic is in. participants will be followed up for 6 months and assessed in regular intervals for the presence of patent and sub-patent malaria. the outcome of the study will contribute to an improved treatment scheme for uncomplicated malaria in this area.


Eligibility criteria:
inclusion criteria: * infection with plasmodium falciparum or p. vivax either alone or mixed * age \>12 months * weight \>5kg * living in the study clusters exclusion criteria: * general danger signs or symptoms of severe malaria * anaemia, defined as hb \<9g/dl * g6pd deficiency (as determined by fst) * pregnant women as determined by urine β-hcg pregnancy test * known hypersensitivity to any of the drugs given
neat - prevention and treatment of overweight and obesity.

Conditions: Overweight; Obesity

Summary: this study will investigate the effect on non-exercise activity thermogenesis (neat) when implementing active workstation at offices compared to conventional office work. the primary hypothesis is that this implementation will lead to a significant increase in time spent walking per day.

neat consists of the energy expenditure of the physical activities that are non sporting-like and that we perform in our everyday life, such as walking, cleaning, shoveling snow etc. which occupation we have play a big role in how much we are able to active our neat during our days and those who have more active jobs can expend up to 1500kcal more per day than those with sedentary jobs. this study aims to try and increase neat at offices where sedentary time often is high. participants will be randomized to either an intervention group or to a control group. participants in the control group will continue to work at their regular desk, but will receive an individual health talk in the beginning of the study where diet and physical activity recommendations will be discussed.participants in the intervention group will receive the same individual health talk and a treadmill desk, which they will use for 12 months at self-selected speed. they will be recommended to walk on the treadmill for at least 1 hour per day.

Eligibility criteria:
inclusion criteria: * office workers with mainly sedentary tasks * bmi 25-40 exclusion criteria: * severe depression and/or anxiety * exhaustion disorder * diabetes mellitus * severe cardiovascular disease * severe kidney disease * musculoskeletal disorders that prohibit walking on a treadmill * contraindications for physical activity * thyroidea illness * pregnancy for fmri-study, additional exclusion criteria are: * implanted metal- or electrical devices * pregnancy * extraneous metal pieces in the body

Keywords: neat treadmill desk
safety and efficacity of corneal collagen crosslinking in infectious keratitis (bacterial and fungal ): randomized,controlled, prospective study. (cxl)

Conditions: Bacterial Keratitis; Fungal Keratitis

Summary: the corneal collagen cross linking is currently used in the treatment of keratoconus but this procedure has also a sterilizing non-specific effect on bacteria and fungus. so the corneal cross linking in association with the antibiotic treatment could result in a reduction of the duration of epithelial complete healing of the cornea.


Eligibility criteria:
inclusion criteria: * infectious bacterial or fungal keratitis with : size \> 2mm or within the central corneal area ( 3mm of the visual axis ) or with a reaction in anterior chamber. * being major responsible. * agreement in writing to participate in the study. * being affiliated to a national insurance scheme. exclusion criteria: * present an infectious keratitis without all the previous criteria. * herpes or acanthamoeba keratitis * preperforated or perforated cornea. general criteria: * pregnant woman. * minors(miners). * adults under guardianship. * patient can not be followed during 3 necessary months. * french speaking patient. * unaffiliated patient in a national insurance scheme. * hiv infected patients

Keywords: infectious keratitis corneal cross linking topical antibiotics
life style and food habits questionnaire in the portuguese population aged 55 or more

Conditions: Age Related Macular Degeneration

Summary: the study population will be selected from the "epidemiological study on the prevalence of age related macular degeneration in portugal" (protocol n. cc-01-2009) where retinal photographic grading (current gold standard for amd assessment) was performed to confirm amd diagnostic. this study provides a population-based sample in which precise and contemporary information on the frequency of nutritional and lifestyle risk factors will be collected, enabling to evaluate whether the separate and/or joint effects of these factors, if found significant, are likely to have a major public health impact in terms of amd.


Eligibility criteria:
inclusion criteria: * subjects included in the epidemiologic study (protocol n. cc-01-2009). (subjects aged over 55 years-old included in health care units of mira or lousã). * written informed consent form signed. exclusion criteria: - none

Keywords: age related macular degeneration food habits life style risk factors questionnaire
study of ivacaftor in subjects with cystic fibrosis (cf) who have a non-g551d cf transmembrane conductance regulator (cftr) gating mutation

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the efficacy and safety of ivacaftor in subjects with cystic fibrosis (cf) who have a non-g551d cystic fibrosis transmembrane regulator (cftr) gating mutation (any one of the following cftr mutations: g178r, g551s, s549n, s549r, g970r, g1244e, s1251n, s1255p, or g1349d).

ivacaftor is the first cftr modulator to show an improvement in cftr function and clinical benefit in subjects with cf. results from phase 3 studies (vx08-770-102 \[study 102\] \[nct00909532\] and vx08-770-103 \[study 103\] \[nct00909727\]) showed that ivacaftor is effective in the treatment of subjects with cf who have the g551d-cftr mutation, as evidenced by sustained improvements in cftr channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments. ivacaftor (trade name kalydeco; 150 mg tablets) was initially approved in the united states for the treatment of cf in subjects 6 years of age and older who have a g551d mutation in the cftr gene.

Eligibility criteria:
inclusion criteria: * male or female with confirmed diagnosis of cf * at least 1 allele of the following cftr gating mutations: g178r, s549n, s549r, g551s, g970r, g1244e, s1251n, s1255p, g1349d * percent predicted forced expiratory volume in 1 second (fev1) greater than or equal to (\>=) 40 percent (%) predicted normal for age, sex, and height * 6 years of age or older * minimum weight of 15 kilogram (kg) at screening * females of childbearing potential must not be pregnant * willing to comply with contraception requirements exclusion criteria: * g551d-cftr mutation on at least 1 allele * history of any illness or condition that might confound the results of the study or pose an additional risk in administering ivacaftor to the subject * an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before the first dose of study drug * history of solid organ or hematological transplantation * history of alcohol, medication or illicit drug abuse within 1 year before the first dose of study drug * ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days before screening * use of inhaled hypertonic saline treatment * use of any inhibitors or inducers of cytochrome (cyp) p450 3a * evidence of cataract or lens opacity at screening
a study of avastin (bevacizumab) in combination with xelox in patients with metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this single arm study will assess the resection rate of liver metastasis, time to disease progression, and safety of neoadjuvant treatment with avastin in combination with oxaliplatin and capecitabine (xelox) in patients with metastatic colorectal cancer with unresectable liver metastasis. patients will receive avastin 5mg/kg iv on day 1 of every 2 week cycle, oxaliplatin 85mg/m2 iv on day 1 of every 2 week cycle, and capecitabine 1000mg/m2 on days 1-5 and 8-12 of every 2 week cycle. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \<=75 years of age; * chemotherapy-naive for stage iv colorectal cancer with unresectable liver metastasis; * \>=1 measurable lesion; * ecog status 0-2. exclusion criteria: * prior exposure to avastin; * clinical or radiological evidence of cns metastases; * uncontrolled hypertension, or clinically significant cardiovascular disease; * ongoing treatment with aspirin (\>325mg/day) or other medications known to predispose to gastrointestinal ulceration.